38
Participants
Start Date
November 30, 2018
Primary Completion Date
December 31, 2023
Study Completion Date
December 31, 2023
AGI-134
AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.
Sheba Medical Center, Ramat Gan
UCLA, Los Angeles
Providence Cancer Institute Franz Clinic, Portland
Rambam Health Care Campus, Haifa
Tel Aviv Sourasky Medical Center, Tel Aviv
Emek Medical Center, Afula
AHS Hospital Corp., Morristown
Hadassah Hebrew University Medical Center, Jerusalem
University of Birmingham, Birmingham
Edinburgh Cancer Research Centre, Edinburgh
The Beatson West of Scotland Cancer Centre, Glasgow
University Collage London, London
The Christie NHS Foundation Trust, Manchester
Churchill Hospital, Oxford
Lead Sponsor
Agalimmune Ltd.
INDUSTRY